Igc Pharma Inc (IGC) Stock Price, Quote & News

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MI...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 983 0998

Website: igcpharma.com

Address:

10224 Falls Road, Potomac, United States

IGC Jul. 10 at 2:37 PM

$IGC IGC Pharma will present its artificial intelligence portfolio at the Alzheimer's Association International Conference (AAIC) 2026 in London. The presentations, led by the Company's AI Team, highlight a broader AI strategy designed to address major bottlenecks in Alzheimer's development, from harmonizing fragmented datasets to identifying patients faster and supporting more targeted clinical workflows. Read the full press release: https://finance.yahoo.com/technology/ai/articles/igc-pharma-showcase-ai-portfolio-130000772.html

0 · Reply

angel6 Jul. 10 at 2:27 PM

$IGC are they getting distracted with too many new ideas instead of concentrating on finishing one idea

0 · Reply

NewsAndFilings Jul. 10 at 11:38 AM

Yesterays Recap: $ADMQ Top YouTube Creator PrestonPlayz Selects ADM Endeavors $IGC Showcase AI Portfolio at AAIC 2026 $GMG $GMGMF Coating THERMAL-XR(R) Reaches Global Benchmark Testing Milestone of 30,000 Hours with No Corrosion

0 · Reply

Deelam Jul. 9 at 9:16 PM

$IGC They keep diluting. Every single day. I'm getting pretty fed up here. CVD shows negative almost every day, no matter the price action. In fact, the more bullish the price action, the bigger the deficit. They're using every opportunity to raise capital, and I've been through this wringer before. Bulls are losing confidence. Positive PRs no longer pop. They've boxed themselves into a corner; it's either positive topline or bust, and there are a lot of longs under water here. I'm starting to worry that the risk profile no longer matches the reward.

0 · Reply

RocketQueen Jul. 9 at 9:12 PM

$IGC plan to buy more soon…

0 · Reply

MsGrumpy Jul. 9 at 5:38 PM

$IGC IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharma-to-showcase-ai-portfolio-at-aaic-2026-including-aha-platform-that-reduced-1188740

0 · Reply

Giants67 Jul. 9 at 2:34 PM

$IGC announced it will showcase its artificial intelligence portfolio across seven scientific presentations at the Alzheimer's Association International Conference (AAIC) 2026, taking place July 12-15 in London. Seven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer's discovery and clinical development

0 · Reply

NewsAndFilings Jul. 9 at 1:14 PM

$IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharma-to-showcase-ai-portfolio-at-aaic-2026-including-aha-platform-that-reduced-1188740

0 · Reply

focafoca99 Jul. 9 at 1:10 PM

$IGC exhibits its AI portfolio at AAIC 2026, featuring the AHA platform that slashed data-harmonization time by 90%. https://www.rapidticker.com/news/igc-igc-pharma-to-showcase-ai-378c6b

0 · Reply

MrTicker Jul. 9 at 1:01 PM

$IGC IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow ACCESS NEWSWIRE 8:00 AM ET 7/9/2026

0 · Reply

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow

2026-07-07T13:26:29.000Z - 4 days ago

IGC Pharma CEO, principal financial officer purchase over $1.15M of stock

Jul 7, 2026, 9:00 AM EDT - 4 days ago

IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

2026-06-23T16:59:03.000Z - 18 days ago

IGC Pharma announced beta version of Agentic Harmonization Assistant

Jun 23, 2026, 8:30 AM EDT - 18 days ago

IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow

2026-06-11T12:43:47.000Z - 4 weeks ago

IGC Pharma reaches 146-patient enrollment target for Phase 2 Calma trial

Jun 11, 2026, 8:30 AM EDT - 4 weeks ago

IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis

Jun 9, 2026, 8:30 AM EDT - 4 weeks ago

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts

2026-06-02T15:20:34.000Z - 5 weeks ago

IGC Pharma adds Mount Sinai clinical site as CALMA trial advances

Jun 2, 2026, 8:30 AM EDT - 5 weeks ago

IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis

May 19, 2026, 5:30 PM EDT - 7 weeks ago

IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment

2026-05-15T13:00:12.000Z - 2 months ago

IGC Pharma to present new Tau-PET biomarker research at Global Tau conference

May 15, 2026, 8:00 AM EDT - 2 months ago

IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

May 15, 2026, 8:00 AM EDT - 2 months ago

IGC Pharma Quarterly report: Q1 2026

Apr 28, 2026, 12:15 PM EDT - 2 months ago

IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase

2026-04-22T13:29:55.000Z - 2 months ago

IGC adds Kerwin Medical Center as clinical site for Phase 2 CALMA trial

Apr 22, 2026, 8:30 AM EDT - 2 months ago

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

2026-04-20T14:17:51.000Z - 2 months ago

IGC Pharma secures Colombian authorization for psilocybin research

Apr 20, 2026, 8:30 AM EDT - 2 months ago

IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia

2026-04-14T12:36:26.000Z - 3 months ago

IGC Pharma reaches 80% enrollment in Phase 2 CALMA trial

Apr 14, 2026, 8:30 AM EDT - 3 months ago

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout

Apr 8, 2026, 12:45 PM EDT - 3 months ago

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

2026-04-07T12:50:45.000Z - 3 months ago

IGC announces activation of new clinical trial sate for Phase 2 CALMA trial

Apr 7, 2026, 8:00 AM EDT - 3 months ago

IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease

2026-03-30T12:38:30.000Z - 3 months ago

IGC Pharma enters national media partnership with New to The Street

Mar 30, 2026, 8:00 AM EDT - 3 months ago

IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness

2026-03-25T12:20:15.000Z - 3 months ago

IGC Pharma, New to The Street launch 12-part national media partnership

2026-03-19T13:12:05.000Z - 4 months ago

IGC Pharma reports 9-month revenue $969K

Mar 19, 2026, 9:00 AM EDT - 4 months ago

IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025

2026-03-18T13:10:59.000Z - 4 months ago

IGC Pharma to showcase AI platform with ADDI at ADPD 2026

Mar 18, 2026, 9:00 AM EDT - 4 months ago

IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026

2026-02-26T13:49:48.000Z - 4 months ago

IGC Pharma files utility patent applications covering AHA framework

Feb 26, 2026, 8:30 AM EST - 4 months ago

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research

Feb 24, 2026, 8:30 AM EST - 4 months ago

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

Feb 23, 2026, 8:30 AM EST - 4 months ago

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

Feb 18, 2026, 1:00 PM EST - 5 months ago

IGC Pharma Transcript: Status update

Feb 17, 2026, 8:30 AM EST - 5 months ago

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

Feb 12, 2026, 8:30 AM EST - 5 months ago

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

Feb 10, 2026, 8:30 AM EST - 5 months ago

IGC Pharma Announces Equity Research Update by Alliance Global Partners

Feb 9, 2026, 8:30 AM EST - 5 months ago

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

Feb 2, 2026, 8:30 AM EST - 5 months ago

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation

Jan 22, 2026, 9:00 AM EST - 6 months ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

Jan 12, 2026, 9:00 AM EST - 6 months ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

Jan 6, 2026, 8:00 AM EST - 6 months ago

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

Jan 5, 2026, 9:00 AM EST - 6 months ago

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

Dec 19, 2025, 9:00 AM EST - 7 months ago

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

Dec 15, 2025, 9:00 AM EST - 7 months ago

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

Dec 10, 2025, 9:00 AM EST - 7 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.

Dec 9, 2025, 9:00 AM EST - 7 months ago

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Dec 3, 2025, 7:00 AM EST - 7 months ago

IGC Pharma Registration statement: Registration Filing

Dec 2, 2025, 9:00 AM EST - 7 months ago

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

Nov 25, 2025, 9:00 AM EST - 8 months ago

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

Nov 17, 2025, 11:00 AM EST - 8 months ago

IGC Pharma Earnings Call Transcript: Q3 2025

Nov 17, 2025, 11:00 AM EST - 8 months ago

IGC Pharma Quarterly report: Q3 2025

Nov 17, 2025, 8:30 AM EST - 8 months ago

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

Nov 17, 2025, 7:00 AM EST - 8 months ago

IGC Pharma Registration statement: Registration Filing

Nov 13, 2025, 9:00 AM EST - 8 months ago

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

Nov 10, 2025, 9:00 AM EST - 8 months ago

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

Nov 3, 2025, 8:52 AM EST - 8 months ago

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

Oct 22, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

Oct 14, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

Oct 10, 2025, 7:50 PM EDT - 9 months ago

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

Oct 7, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

Sep 29, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

Sep 24, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

Sep 22, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Sep 9, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

Sep 2, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

Aug 28, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

Aug 27, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

IGC Jul. 10 at 2:37 PM

0 · Reply

angel6 Jul. 10 at 2:27 PM

$IGC are they getting distracted with too many new ideas instead of concentrating on finishing one idea

0 · Reply

NewsAndFilings Jul. 10 at 11:38 AM

0 · Reply

Deelam Jul. 9 at 9:16 PM

0 · Reply

RocketQueen Jul. 9 at 9:12 PM

$IGC plan to buy more soon…

0 · Reply

MsGrumpy Jul. 9 at 5:38 PM

0 · Reply

Giants67 Jul. 9 at 2:34 PM

0 · Reply

NewsAndFilings Jul. 9 at 1:14 PM

0 · Reply

focafoca99 Jul. 9 at 1:10 PM

$IGC exhibits its AI portfolio at AAIC 2026, featuring the AHA platform that slashed data-harmonization time by 90%. https://www.rapidticker.com/news/igc-igc-pharma-to-showcase-ai-378c6b

0 · Reply

MrTicker Jul. 9 at 1:01 PM

$IGC IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow ACCESS NEWSWIRE 8:00 AM ET 7/9/2026

0 · Reply

RocketQueen Jul. 9 at 2:30 AM

$IGC severely undervalued.

0 · Reply

whob007 Jul. 8 at 8:23 PM

$IGC When are topline results likely? Although IGC has not provided an official date, based on the trial's progress and standard timelines for a Phase 2 study: Most likely: Late Q3 to early Q4 2026 (August–October 2026). If patient follow-up or data cleaning takes longer than expected, the readout could slip into late 2026. This is an estimate rather than company guidance.

0 · Reply

Giants67 Jul. 8 at 5:07 PM

$IGC IGC Pharma, Inc. (NYSE American: IGC) CEO Ram Mukunda on “The Street Reports Podcast” https://thestreetreports.com/alzheimers-biotech-igc-pharma-inc-nyse-american-igc-ceo-ram-mukunda-on-the-street-reports-podcast-listen-now/

0 · Reply

GordoHLYK13 Jul. 8 at 2:36 PM

$IGC https://youtu.be/FnzpODwOS5o?is=Kb_ABH299kgGj8BS Shorts will get squeezed

0 · Reply

Jdstoner30 Jul. 8 at 1:18 PM

$IGC what do we think?

2 · Reply

NewsAndFilings Jul. 8 at 11:59 AM

Yesterdays Recap: $TERS Appoints Cynthia Maloney $SSII SSICRS Graduates 1st Class $ALST MOU Reality Series $IGC Buys Over $1.15 Million Common Stock $DOSE.CN $RDTCF MOU nicotine products $GMG $GMGMF June 2026 Sales Orders of over A$400K $CBDL Launches Breakthrough Skincare Line

0 · Reply

GordoHLYK13 Jul. 8 at 1:33 AM

$IGC https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharma-ceo-and-principal-financial-officer-purchase-more-than-1.15-million-of-com-1187333 This wasn’t just dilution—it was a major insider confidence move. 🔥 The CEO and PFO converted $1.15M into restricted common shares, including over $552K of their own cash they had previously loaned the company. 🔥 No warrants. No preferred shares. No sweetheart deal. They took the same common stock at full market price ($0.27). With the AI presentation and CALMA Phase 2 catalyst approaching, management chose stock over cash. While insiders can be wrong, many investors view that as a strong sign of confidence in the company’s future

0 · Reply

RocketQueen Jul. 8 at 12:01 AM

$IGC CEO and CFO both just made direct buys of IGC stock.

0 · Reply

focafoca99 Jul. 7 at 7:14 PM

$IGC announced insider purchase of 4.27M shares, canceling $1.15M debt and boosting CEO/CFO ownership. https://www.rapidticker.com/news/igc-igc-pharma-ceo-and-principal-8b8b5c

0 · Reply

MsGrumpy Jul. 7 at 6:59 PM

$IGC IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharma-ceo-and-principal-financial-officer-purchase-more-than-1.15-million-of-com-1187333

0 · Reply

IGC Jul. 7 at 5:22 PM

$IGC IGC Pharma announced that CEO Ram Mukunda and Principal Financial Officer Claudia Grimaldi purchased an aggregate of 4,274,853 shares of IGC common stock directly from the Company at $0.27 per share. The transaction was completed through the cancellation of approximately $1.15 million in outstanding amounts owed by the Company, including more than $552,362 of personal cash previously advanced to IGC. Read the full press release: https://finance.yahoo.com/healthcare/articles/igc-pharma-ceo-principal-financial-130000873.html #alzheimersresearch #igcpharma

0 · Reply

Giants67 Jul. 7 at 4:55 PM

$IGC IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company Senior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGC

0 · Reply

Market Cap	27.23M
Revenue (ttm)	1.27M
Net Income (ttm)	-7.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.15

Volume	462,200
Avg Vol	605,446
Day's Range	N/A - N/A
Shares Out	100.09M
Stochastic %K	43%
Beta	0.45
Analysts	Sell
Price Target	$4.25